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Abstract
Background: The incidence of community-acquired pneumonia and lower respiratory tract infection rises considerably
in later life. Immunoglobulin M (IgM) antibody levels to pneumococcal capsular polysaccharide are known to decrease
with age; however, whether levels of IgM antibody to pneumococcal proteins are subject to the same decline has not yet
been investigated.
Methods: This study measured serum levels and binding capacity of IgM antibody specific to the pneumococcal surface
protein A (PspA) and an unencapsulated pneumococcal strain in serum isolated from hospital patients aged < 60 and≥
60, with and without lower respiratory tract infection. A group of young healthy volunteers was used as a comparator to
represent adults at very low risk of pneumococcal pneumonia. IgM serum antibody levels were measured by enzyme-
linked immunosorbent assay (ELISA) and flow cytometry was performed to assess IgM binding capacity. Linear regression
and one-way analysis of variance (ANOVA) tests were used to analyse the results.
Results: Levels and binding capacity of IgM antibody to PspA and the unencapsulated pneumococcal strain were
unchanged with age.
Conclusions: These findings suggest that protein-based pneumococcal vaccines may provide protective
immunity in the elderly.
Trial registration: The LRTI trial (LRTI and control groups) was approved by the National Health Service Research
Ethics Committee in October 2013 (12/NW/0713). Recruitment opened in January 2013 and was completed in July
2013. Healthy volunteer samples were taken from the EHPC dose-ranging and reproducibility trial, approved by the
same Research Ethics Committee in October 2011 (11/NW/0592). Recruitment for this study ran from October 2011
until December 2012. LRTI trial: (NCT01861184), EHPC dose-ranging and reproducibility trial: (ISRCTN85403723).
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Background
Community-acquired pneumonia (CAP) has an inci-
dence of 5–11 per 1000 adult population [1, 2], with an
associated mortality between 5 and 20%, increasing to
50% in cases admitted to the intensive care unit [3]. The
most common cause of CAP is Streptococcus pneumoniae
[4]. Eighty per cent of CAP occurs in people ≥60 years
[5–7], and this has been attributed to immune senescence,
impairment of protective airway reflexes [8], reduced airway
mucociliary clearance [9, 10] and alterations in respiratory
tract immune function [11, 12]. Polysaccharide-based vac-
cines are recommended for older adults: the pneumococcal
conjugate vaccine (PCV) is now licensed for adults over the
age of 50 in the United States (US) and the pneumococcal
polysaccharide vaccine (PPV) is recommended to people
over 65 years of age in the United Kingdom (UK). However,
the true levels of protection conferred by these vaccines in
older adults are unclear [13–16]. They also have significant
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short-comings with regards to limited pneumococcal sero-
type coverage. Protein-based vaccines are being investigated
as alternative immunization strategies, on the basis that
they could provide full serotype coverage by targeting con-
served proteins. As immunogenicity in vivo will depend on
exposure to the host immune system, surface-expressed
proteins are obvious potential vaccine candidates.
The protective role of antibody responses to pneumo-
coccal infection is well described. IgM antibodies are the
first class of antibodies to be produced in a primary re-
sponse to microbial challenge. Although they bind with
low affinity they exhibit a broad specificity to a variety of
antigens [17]. Murine models have demonstrated that
the passive transfer of IgM antibodies targeting pneumo-
coccal polysaccharides can improve survival following a
lethal pneumococcal challenge, suggesting that IgM anti-
body may be sufficient to confer protection against
pneumococcal disease [18]. The therapeutic potential of
an immunoglobulin preparation enriched with IgM for
the treatment of severe CAP is under investigation [19].
Levels of antibodies to pneumococcal polysaccharides
decline with aging, with IgM levels being more affected
than the IgG subclass [20–22]. Levels of IgG to several
pneumococcal protein antigens are also reduced in the
elderly [22].
Pneumococcal surface protein A (PspA) is a major and
well characterized virulence factor of the pneumococcus.
Antibodies directed against PspA augment C3 depos-
ition, and immunization with PspA confers protection to
a variety of murine infection models [23, 24]. PspA is
expressed in the majority of clinically important
pneumococcal serotypes [25] and clade 4 in particular
exhibits broad cross reactivity [26], allowing for sensitive
detection of anti-PspA antibodies.
Despite evidence that IgM antibodies may play a role
in anti-pneumococcal defence, and that IgG antibodies
to pneumococcal proteins have protective potential, the
impact of age on levels of IgM antibodies to pneumo-
coccal proteins in humans has not been investigated.
This study seeks to address this knowledge gap by inves-
tigating changes in levels and function of IgM antibodies
against pneumococcal proteins in relation to aging and
lower respiratory tract infection (LRTI) using the PspA
clade 4 (PspA4) and an unencapsulated pneumococcal
strain. It was hypothesised that as subjects age, levels
and binding capacity of IgM antibodies against pneumo-
coccal proteins in serum would be impaired and that pa-
tients hospitalized with LRTI would have lower IgM
levels and functionality when compared to controls.
Methods
Study subjects
Serum samples used in this study were collected as part
of two clinical trials, both of which have already had
their primary end-points reported elsewhere: the LRTI
trial [27] and the dose-ranging trial [28]. The volunteers
can be separated into three cohorts: LRTI, control (both
from the LRTI trial) and healthy (taken from the
dose-ranging trial).
The LRTI cohort consisted of patients with a diagnosis
of LRTI, based on presentation with symptoms of re-
spiratory infection with ≥2 of the following clinical signs:
“cough, breathlessness, pleuritic chest pain, fever and
increased or new sputum production” [27]. Without
additional radiological consolidation, LRTI patients can-
not be considered to have CAP, but this broader cohort
was chosen because of its clinical relevance in the UK
hospitals setting [27].
The control cohort comprised patients admitted to
hospital for reasons other than LRTI. They had no re-
spiratory symptoms, and were age- and gender-matched
to the LRTI patients.
The healthy cohort was formed of healthy volunteers
aged 18–60 with no concurrent co-morbidities.
Sample collection
Nasal washes and serum samples were taken from LRTI
and control group volunteers within 3 days of hospital
admission. Baseline nasal washes and serum samples
were taken from healthy volunteers by appointment.
Nasal washes were processed as described previously
[27, 28] and used to determine pneumococcal carriage
status and density by classical microbiology and by lytA
qPCR. Urine from LRTI and control volunteers was col-
lected to perform the BinaxNOW (Alere International
Ltd., Ireland) (urine chromatography) test.
Bacterial strains
An unencapsulated D39 strain with deleted cpsD
(D39-DΔ) [29] (donated by Professor Jeremy S. Brown,
University College, London) was cultured in
Todd-Hewitt broth with 0.5% yeast extract (THY) until
the mid-log phase. Bacteria was then pelleted, washed in
phosphate buffered saline (PBS) and either used for
whole cell ELISA (WCE) or resuspended in THY+ 20%
glycerol and stored at − 80 °C for later use in an im-
munoglobulin binding assay.
Enzyme-linked immunosorbent assay (ELISA)
ELISA was used to quantify levels of IgM antibodies in
the serum samples as previously described [30]. Briefly,
96-well plates (Nunc, Denmark) were coated with car-
bonate/bicarbonate buffer containing capture antigens/
antibodies. The capture antigens/antibodies included
1 μg/ml recombinant PspA4 (kindly donated by Dr.
Eliane Miyaji, Butantan Institute, Sao Paulo, Brazil), the
non-encapsulated D39-DΔ pneumococcal strain and
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anti-human IgM μ chain-specific antibody (I2386,
Sigma-Aldrich, St Louis, Missouri, USA).
Plates were washed then blocked with 1% bovine
serum albumin(BSA)-PBS before adding serial dilutions
of serum samples. Standard curves for calculating total
IgM were made using purified total IgM from serum
(I8260, Sigma-Aldrich, USA) at a level of 1 mg/ml. WCE
and anti-PspA4 values were based on a standard pool
serum with an IgM level of 4000 arbitrary units/μl (do-
nated by Prof David Briles, University of Alabama).
IgM was bound to a goat anti-human IgM polyclonal
antibody conjugated to biotin (Abcam, Cambridge, UK).
The conjugate was quantified by streptavidin-alkaline
phosphatase (Bio-Rad Laboratories, Hemel Hempstead,
UK) using 4-Nitrophenyl phosphate disodium salt hexa-
hydrate (N9389, Sigma-Aldrich, USA) as the substrate
for development. Absorbance at 405 nm wavelength was
determined using the Fluostar Omega® (BMG Labtech,
Ortenberg, Germany) plate reader. A standard curve was
fitted using a 4-parameter fit model.
Flow cytometry
Immunoglobulin deposition on whole live unencapsulated
pneumococci was assayed using a modification of a pub-
lished flow cytometry assay [31]. Briefly, D39-DΔ resus-
pended in THY + 20% glycerol was grown to mid-log
phase in THY media with erythromycin, before two cycles
of washing with PBS. Serum from patient groups was
pooled and diluted in PBS at ratios of 1:2 and 1:20. Fixed
volumes of the bacterial suspension were washed and re-
suspended in 100 μl of pooled serum before incubation
for 30 min at 37 °C. Samples were pelleted, resuspended
in IgM-PE-Cy5 (Clone G20–127, BD Biosciences, Franklin
Lake, NJ, USA) and incubated for 20 min at 37 °C. Bac-
teria were washed and the level of IgM binding measured
by flow cytometry using a BD LSR II (BD Biosciences,
New Jersey, USA). The level of binding was calculated as
the percentage of the bacterial population positive for IgM
deposition multiplied by the geometric mean fluorescence
of the bacterial population positive for IgM.
Statistical analysis
Linear regression analysis was used to correlate levels
of antibodies with age. Antibody levels were log
transformed to obtain normal distribution then ana-
lysed by one-way ANOVA with the Bonferroni correc-
tion to compare levels between the three groups.
Analyses were performed using GraphPad Prism v5
(GraphPad Inc., California, USA) and significance was
set at p < 0.05.
Results
Clinical trials
Overall, 38 hospital inpatients were enrolled in the
LRTI trial, equally divided between patients with a
diagnosis of LRTI (n = 19) and controls (n = 19). All
LRTI patients, and 3 control patients, had been
treated with antibiotics before recruitment to this
study [27]. However, none of the control patients pre-
sented with a symptomatic infection. 10 volunteers
were chosen from the dose-ranging study to be in-
cluded in this analysis as healthy volunteers.
Table 1 outlines cohort characteristics. The mean
age for LRTI patients was 64.5 years ±15.8 and
64.6 years ±14.5 for the control group. The mean
age of the healthy group was 21.2 years ±2.4. A
similar percentage of volunteers were female in all
three cohorts: 53% for LRTI and control groups, and
50% for healthy volunteers. Risk factors for pneumo-
coccal infection were recorded for both LRTI and
control cohorts. Vaccination with PPV and contact
with children was similar between both groups,
whereas LRTI patients were more likely to be
smokers, use corticosteroids and have COPD and/or
asthma (Table 1).
Evidence was found of recent pneumococcal exposure
in 50% (19/38) of the study’s patients, either by detection
Table 1 Study population characteristics
LRTI (n = 19) Controls (n = 19) Healthy volunteers (n = 10)
Age (mean ± SD) (yr) 64.5 (15.8)
10 (53)
64.6 (14.5)
10 (53)
21.2 (2.4)
5 (50)
Female gender (n [%])
Smoker/ex-smoker (n [%]) 15 (79) 10 (53) 0 (0)
PPV (n [%]) 7 (37) 8 (42) 0 (0)
Contact with children (n [%]) 10 (53) 12 (63) 0 (0)
Corticosteroid use (n [%]) 16 (84) 3 (16) 0 (0)
COPD (n [%]) 8 (42) 2 (11) 0 (0)
Asthmatic (n [%]) 5 (26) 1 (5) 0 (0)
COPD, chronic obstructive pulmonary disease; LRTI, lower respiratory tract infection; PPV, pneumococcal polysaccharide vaccine
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of pneumococcal nasal carriage or BinaxNOW (urine
immunochromatography) test [27]. Of these, 11
belonged to the LRTI cohort. There was no significant
difference in IgM antibody levels between pneumococcal
carriers and non-carriers, nor was there any correlation
between IgM antibody levels and carriage density by
qPCR (data not shown).
Effect of age on immunoglobulin M antibody levels in
serum
While the total levels of IgM trended to increase with in-
crease of age (r2 = 0.15, p = 0.006) (Fig. 1a), no correlation
was observed for levels of specific pneumococcal IgM
a
b
c
Fig. 1 Levels of IgM in relation to age. Levels of (a) total IgM, (b)
IgM to the unencapsulated D39-ΔD pneumococcus and to the (c)
Pneumococcal Surface Protein A (PspA4) were plotted against
volunteer age. Correlations were analysed using linear
regression analysis
a
b
c
Fig. 2 Levels of IgM in relation to LRTI. The level of total IgM was
examined for patients with LRTI, hospital Controls and a young
cohort of Healthy volunteers. Levels of (a) total IgM, (b) IgM to the
unencapsulated D39-ΔD pneumococcus and to the (c)
Pneumococcal Surface Protein A (PspA4) are shown. Mean values ±
SD are shown. * p < 0.05 using ANOVA with Bonferroni’s correction
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antibody and age: D39-DΔ (r2 = 0.07, p = 0.05) and PspA4
(r2 = 0.005, p = 0.60) (Figs. 1b and c).
Effect of lower respiratory tract infection on
immunoglobulin M levels
There was no difference in total IgM levels between LRTI
and control groups. The LRTI group had higher levels of
total IgM when compared to the healthy group (p= 0.01 for
ANOVA analysis, p < 0.05 for the difference between LRTI
and healthy groups) (Fig. 2a). No significant difference was
observed in IgM antibody levels to D39-DΔ (p= 0.64 for
ANOVA analysis) or to PspA4 (p= 0.14 for ANOVA ana-
lysis) between any of the groups (Figs. 2b and c).
Immunoglobulin binding to whole-cell unencapsulated
pneumococcus
The immunoglobulin binding assay was performed to
assess changes in the binding capacity of IgM with aging
a
b
Fig. 3 Flow cytometric assessment of IgM binding to pneumococcus surface. Pooled sera from different volunteer groups were added to
bacteria. Two experiments using different dilutions (1:2 and 1:20) of sera were performed. a Histogram of surface binding of IgM to intact
pneumococcus D39-DΔ. b Surface binding of IgM from pooled serum samples expressed as the percentage of the bacterial population positive
for IgM deposition multiplied by the geometric mean fluorescence of the bacterial population positive for IgM
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and LRTI status. Sera from ≥60 control group showed
no decrease in binding compared to younger volunteers
from the healthy group (Figs. 3a and b). Contrary to the
study’s initial hypothesis, the ≥60 LRTI group exhibited
the highest level of IgM binding while the < 60 control
group showed the lowest levels of binding.
Discussion
These results demonstrate that the levels and binding
capacity of IgM to pneumococcal proteins are unaltered
with aging. Patients with LRTI did not show decreased
IgM antibody to D39-DΔ or PspA4 compared to either
the control or healthy groups. The study observed
higher IgM binding to pneumococcus in a flow cytome-
try assay for sera from LRTI patients over 60 years.
High levels of total IgM in patients with LRTI cannot
be an artefact of current infection, but rather of aging,
because control patients without infection presented
with similar total IgM levels, but the healthy group had
significantly lower total IgM levels. Although only IgM
antibodies against pneumococcal polysaccharides and
proteins can be expected to confer protection against
pneumococcal infection, it is nevertheless interesting to
note that total IgM antibody levels are maintained des-
pite immune senescence.
A study of IgM levels in mice found that total IgM
levels were increased in older animals [32]. However, the
authors found that anti-pneumococcal protein IgM anti-
body levels (as indicated by antibodies to phosphoryl
choline, a pneumococcal cell wall antigen) dropped with
age. This discrepancy with the present study’s data could
be explained by the different choice of antigen or the
limitation of animal models (which are immunologically
naïve) to represent human responses (which are fre-
quently re-challenged by in vivo exposure to pneumo-
coccus through nasal carriage) [28]. IgM from older
mice (18- or 24-month) was less protective against
pneumococcal challenge when compared to younger
mice (3-month) [32]. The present study showed, how-
ever, that IgM in adults over the age of 60 retains the
ability to bind to non-encapsulated S. pneumoniae.
In whole-cell ELISA, in addition to surface protein an-
tigens, cell wall antigens are also present, to which IgM
binding may occur; however, whether these antibodies
confer meaningful protection has been questioned [33,
34]. It has been suggested that bacterial autolysis during
the overnight coating step releases internal antigens
which would not in vivo be presented to the immune
system [31]. Antibodies to these internal and cell wall
antigens could conceivably lead to an overestimation of
levels of IgM antibody against surface protein antigens.
To address this issue, the study also used a flow cyto-
metric approach to evaluate antibody binding to intact
pneumococcus. Whereas cohort and age showed no
impact on antibody levels measured by whole cell
ELISA, differences were observed in antibody binding as
assessed by flow cytometry. This discrepancy could be
explained by bacterial rupture.
Limitations of this study include the small number of
samples and the unknown etiology of LRTI of these pa-
tients. This study cohort also had significant heterogen-
eity with respect to many factors affecting
immunoglobulin levels; for example, vaccination status,
co-morbidities, corticosteroid treatment, and history of
previous pneumococcal infection [27]. Furthermore, 12
of the LRTI patients received Clarithromycin prior to re-
cruitment. The activities of 14-membered macrolide an-
tibiotics are known to exert immunomodulatory effects
[35] and this may have affected IgM responses to
S.pneumoniae in this cohort.
Conclusions
In summary, these findings suggest that IgM antibodies
against pneumococcal proteins do not decrease with age
and this warrants further investigation into IgM anti-
bodies against pneumococcal proteins and its role in im-
munity through pneumococcal protein vaccination.
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